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Abstract: Objective: Pulmonary valve regurgitation (PR) and right ventricular (RV) dilatation are
important residual findings after surgical repair of tetralogy of Fallot (TOF). We sought to describe the
natural course of RV dilatation over time in patients with severe PR after TOF repair and to determine
risk factors for quick progression of RV dilatation and dysfunction. Methods: Data of 85 consecutive TOF
patients with PR and RV dilatation, undergoing serial cardiovascular magnetic resonance (CMR) scans
between July 2002 and December 2016 in two institutions, were retrospectively reviewed. The dataset
was analyzed regarding right and left ventricular (LV) volume and function and potential risk factors
of progressive RV dilatation. Results: There was no significant increase in RV end-diastolic volumes
(RVEDVi) indexed body surface area (BSA) (median 150 [81-249] vs. 150 [82-260] mL/m2) and end-
systolic volumes indexed for BSA (RVESVi) (75 [20-186] vs. 76 [39-189] mL/m2) between the first and
last CMR in the overall group. Similarly, there were no significant changes in LV volumes indexed for BSA
(LVEDVi 78 [56-137] vs. 81 [57-128] mL/m2 and LV end-systolic volume index 34 [23-68] vs. 35 [18-61]
mL/m2). Global function remained also unchanged for both ventricles. RVEDVi increased statistically
significantly (฀20 mL/m2) in twenty patients (24%) from 154 mL/m2 (87-237) to 184 mL/m2 (128-260,
P < 0.001). LV dimensions showed a similar trend with LVEDVi increase from 80 ml/m2 (57-98) to 85
ml/m2 (72-105, P = 0.002). Shorter time interval between repair and first CMR was the only risk factor
predictive for progressive RV dilatation. Conclusion: In the majority of patients with repaired TOF and
severe PR, RV dilatation is unchanged during a follow-up of 3 years. RV dilatation seems to progress
early after surgery and subsequently stabilize. RV dilatation significantly progresses in a subgroup of
24% of patients, with a shorter time interval since surgical repair.
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ABSTRACT
Objective : Pulmonary valve regurgitation (PR) and right ventricular (RV) dilatation are important 
residual findings after surgical repair of tetralogy of Fallot (TOF). We sought to describe 
the natural course of RV dilatation over time in patients with severe PR after TOF repair 
and to determine risk factors for quick progression of RV dilatation and dysfunction.
Methods : Data of 85 consecutive TOF patients with PR and RV dilatation, undergoing serial 
cardiovascular magnetic resonance (CMR) scans between July 2002 and December 2016 in two 
institutions, were retrospectively reviewed. The dataset was analyzed regarding right and left 
ventricular (LV) volume and function and potential risk factors of progressive RV dilatation
Results : There was no significant increase in RV end‑diastolic volumes (RVEDV
i
) indexed body 
surface area (BSA) (median 150 [81–249] vs. 150 [82–260] mL/m2) and end‑systolic volumes 
indexed for BSA (RVESV
i
) (75 [20–186] vs. 76 [39–189] mL/m2) between the first and last 
CMR in the overall group. Similarly, there were no significant changes in LV volumes 
indexed for BSA (LVEDV
i
 78 [56–137] vs. 81 [57–128] mL/m2 and LV end‑systolic volume 
index 34 [23–68] vs. 35 [18–61] mL/m2). Global function remained also unchanged for 
both ventricles. RVEDV
i
 increased statistically significantly (≥20 mL/m2) in twenty 
patients (24%) from 154 mL/m2 (87–237) to 184 mL/m2 (128–260, P < 0.001). LV dimensions 
showed a similar trend with LVEDVi increase from 80 ml/m2 (57–98) to 85 ml/m2 (72–105, 
P = 0.002). Shorter time interval between repair and first CMR was the only risk factor 
predictive for progressive RV dilatation.
Conclusion : In the majority of patients with repaired TOF and severe PR, RV dilatation is unchanged 
during a follow‑up of 3 years. RV dilatation seems to progress early after surgery and 
subsequently stabilize. RV dilatation significantly progresses in a subgroup of 24% of 
patients, with a shorter time interval since surgical repair.
Keywords : Pulmonary regurgitation, pulmonary valve replacement, right ventricular dilatation, 
tetralogy of Fallot
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CMR technique
In Zurich, CMR scans were performed with a 1.5 T 
systems (Signa MR/i Twinspeed or Discovery MR 
450, GE Medical Systems, Waukesha, Wisconsin, USA) 
using phased-array cardiac coils. After obtaining 
coronal, sagittal, and axial localizers, steady-state 
free precession (SSFP) cine images were acquired in a 
horizontal and vertical long-axis plane, as well as in 
a short-axis plane covering both ventricles from the 
base (plane of the atrioventricular valves) to the apex. 
Slice thickness was 5–8 mm with a gap of 0–2 mm as 
appropriate for body size for obtaining a total of 12–13 
slices. All images were acquired during breathholding. 
The parameters of the SSFP sequence were as follows: 
20 phases/cardiac cycle, echo time (TE)  1.5–1.8 ms, 
repetition time (TR) 2.8–3.1 ms, flip angle 45°, bandwidth 
125 kHz, matrix 224 × 224, number of excitations 1, field 
of view 250–350 mm, views per segment 6–12 depending 
on heart rate, and retrospective cardiac gating.
In Rome, CMR examinations were performed with a 1.5 T 
scanner  (Achieva, Philips Medical, Best, The Netherlands) 
using a five-channel phased-array cardiac coil and an 
identical imaging protocol. The parameters of the SSFP 
sequence were as follows: 30 phases/cardiac cycle, 
TE 1.45 ms, TR 2.9–3.3 ms, flip angle 60°, bandwidth 
1750 kHz, acquisition matrix 164 × 162, number of 
averages 1, field of view 250–350 mm, views per segment 
10–13 depending on heart rate, and retrospective cardiac 
gating.
All images  were postprocessed on commercially available 
workstations, and ventricular parameters were calculated 
with dedicated cardiac software (Mass Versions 4–8, 
MEDIS, Medical Imaging Systems, Leiden, The Netherlands, 
and Viewform, Philips Medical, Best, The Netherlands, 
respectively, as previously described.[10] All ventricular 
parameters were indexed for BSA.
Moderate  PR was defined as a regurgitation fraction 
of ≥20%. Definitions of RV dilatation, normal RV ejection 
fraction (EF) % ≥50, and left ventricular (LV) EF % ≥55 
were based on the existing normal values.[10-13]
Similarly, the published variability of  CMR measurements 
helped to define a significant difference in ventricular 
volume, if this changed more than 10% of its initial value; 
thus, we defined a significant progression in RV dilation if 
the RV end-diastolic volume indexed (RVEDV
i
) increased 
by more than 20 ml/m2.[10]
Statistical analysis
Contiguous data were reported as median and range. 
Categorical data were expressed as percentage. Data 
were tested for normality using the D’agostino and 
Pearson’s normality test. As not all data were normally 
distributed, nonparametric tests were chosen for the 
statistical analysis.
INTRODUCTION
Pulmonary valve regurgitation (PR) is an important 
residual finding after surgical repair of tetralogy 
of Fallot (rTOF). Severe PR causes progressive right 
ventricular (RV) dilatation, with a potential negative 
cascade including RV dysfunction, deterioration of 
physical performance, life-threatening arrhythmias, 
and eventually premature death.[1,2] Thanks to new 
interventional techniques, there is currently a trend for 
timely insertion of a new pulmonary valve.[3] However, the 
correct timing for pulmonary valve replacement (PVR) 
is still a subject of debate, and little is known about 
the progression rate of RV dilatation. With growing 
interest in the early identification of deteriorating 
ventricular volumes, clinical guidelines recommend 
serial cardiovascular magnetic resonance (CMR) every 
2–3 years.[4] However, still, there are inconsistent 
observations, with some studies showing progression 
of RV dilatation over time in rTOF patients and 
others indicating stable parameters in the overall 
population.[5-8] As an alternative to the idea of a 
continuous RV dilatation, there is some evidence 
suggesting that the RV dimensions may enlarge soon 
after repair and remain almost unchanged during longer 
follow-up.[9]
This  study was aimed to describe the natural course 
of RV dilatation over time in patients with PR after TOF 
repair, as measured by serial CMR, and to determine 




Data of all consecutive rTOF patients with PR and 
RV dilatation, undergoing serial CMR scans between 
July 2002 and December 2016 in two institutions 
(University Children’s Hospital Zurich, Switzerland; 
Bambino Gesù Children’s Hospital, Rome, Italy), were 
retrospectively reviewed. Demographic and clinical data 
were recorded from the medical records and included 
gender, diagnosis, age at surgical repair, surgical 
technique, and age and body surface area (BSA) at the 
time of each CMR.
Inclusion  criteria were diagnosis of TOF and its 
var iants ,  inc luding pulmonary atres ia  with 
ventricular septal defect and double-outlet right 
ventricle of Fallot type, and at least two consecutive 
CMR examinations in the same patient, without any 
intervention in between.
Exclusion  criteria were diagnosis of pulmonary atresia 
with intact ventricular septum, surgical repair at 
age ≥30 years, and incomplete CMR dataset.
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Changes  of the ventricular parameters over time were 
tested with the Wilcoxon signed-rank test. All data of the 
group with significant RVEDV
i
 progression (≥20 ml/m2) 
were compared with the same data of the group without 
significant RVEDV
i
 progression (≤20 ml/m2). Continuous 
parameters were compared using the Mann–Whitney 
U-test. Categorical data were tested with the Chi-square 
test and the Fisher’s exact test. The correlation between 
RV end-diastolic volume (RVEDV) changes over time  and 
continuous parameters was assessed with the Spearman’s 
rho correlation coefficient. These parameters included 
age at surgical repair, surgical technique used for repair, 
age at first CMR, time from surgical repair to first CMR, 
LV volumes and biventricular function at first CMR, and 
BSA changes.
The results were two tailed, and P < 0.05 was considered 
statistically significant. All statistical analyses were 
performed with SPSS Inc., Version 22.0 (Chicago, IL, 
USA) and Graphpad Prism Inc., Version 5 (San Diego, 
CA, USA) software.




Eighty-five consecutive patients (39 females) with PR and 
RV dilatation who underwent at least two (range 2–6) CMR 
examinations, without having any intervention between 
the first and last CMR scan, were included in the study. 
The diagnosis was repaired TOF in 80, double-outlet 
right ventricle of Fallot type in three, and pulmonary 
atresia (PA) with ventricular septal defect in two patients. 
Patient characteristics are presented in Table 1.
Surgical repair was performed at a median age of 
1 year (2 months–12 years).  The RV outflow tract had 
been reconstructed using the transannular patch technique 
in 57 (67%) patients, an infundibular patch in 8 (9%), a 
commissurotomy with infundibular resection in 5 (6%), and 
an isolated insertion of a homograft in 9 (11%) patients. 
The operation technique was unknown in six patients (7%).
The first CMR examination was performed at a median 
age of 13.7 (1.4–45)  years, corresponding to 12.6 (1–40) 
years after surgery. The last CMR examination was taken 
at a median age of 18.3 (7 months–49 years) years. The 
median time interval between the first and last CMR 
scans was 3.4 (6 months–12.2 years) years. There was 
no significant difference between the time interval in 
the progression group (3.2 years [6 months–11.5 years]) 
versus the stable group (4 years [1.3 years–12.2 years]).
Two-thirds (62%)  of all patients were younger than 
16 years at the first CMR, and 40% at the last CMR 
examination.
Ventricular volumes
The volumes of both ventricles at the time of first CMR 
are shown in Table 2. There was significant RV dilatation 
with a median RVEDV of 150 ml/m2 (81–249). During 
follow-up, no significant increase in RV or LV dilatation 
was observed in the overall patient group [Table 2].
RVEDV
i
 increased signif icantly (≥20 mL/m 2) 
in twenty patients (24%) [Figure 1]. The median 
increase for RVEDV
i
 from 154 mL/m2 (87–237) to 
184 mL/m2 (128–260) [Table 3], corresponded to the 
annual increase rate of 8 ml/m2/years (2–28) for the 
RVEDV. Interestingly, in this group, RVESV
i
 and LV 
volume indexed, but not LV end-systolic volume index, 
significantly enlarged as well [Table 3]. Both ventricles 
did not show any changes in EF%.
Factors related to progressive right ventricular 
dilatation
The shorter time interval between repair and first 
CMR was related to progressive RV dilatation, being 








Gender female 39 8 31
Age at first CMR 13.7 (1‑45) 13 (1‑43) 13.7 (3‑45)
Time of surgery to first CMR 12.6 (1‑40) 11.1 (1‑40) 13.2 (3‑40)
Number of CMR examinations 2 (2‑6) 3 (2‑4) 2 (2‑6)
Diagnosis
TOF 80 19 61
DORV (Fallot type) 3 0 3
PA/VSD 2 1 1
Type of repair
Transannular patch 57 13 44
Infundibular patch 8 1 7
Commissurotomy with infundibular resection 5 3 2
Homograft 9 2 7
Unknown 6 1 5
CMR: Cardiac magnetic resonance, TOF: Tetralogy of Fallot, DORV: Double‑outlet right ventricle, PA/VSD: Pulmonary atresia/ventricular septal defect
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11.1 (12 months–40 years) years in the group 
with significant RVEDV increase, compared to 13 
(3–40) years in the group without progressive RV 
dilatation (P = 0.03) [Figure 2]. In contrast, presence of 
a transannular patch, initial RV volume, BSA changes, 
LV volumes and biventricular function at first CMR, 
and age at repair were not associated with a significant 
progression of RV dilatation.
DISCUSSION
The present study shows that RV volumes significantly 
increase in only 24% of the patients, over an average time 
period of 3.4 years. In this patient subgroup, the annual 
rate of increase was small and RV EF remained preserved. 
The only factor related to progressive RV enlargement 
was the time interval between surgical repair and the 
CMR examination. This observation supports the idea 
of Greutmann that RV dilatation represents an early 
postoperative remodeling after TOF repair, which tends 
to remain stable during follow-up, as we have observed 
for the overall group of patients.[9]
These results are in line with  two other previous studies 
reporting no significant progression in the majority 
of rTOF patients[5,6] and consolidate the opinion that 
indication for PVR should be carefully pondered, 
including follow-up data in asymptomatic patients in 
order to detect the individuals in whom RV deterioration 
may occur.
The ideal timing for  PVR in asymptomatic rTOF patients 
with severe PR and RV dilatation is still the subject of 
debate. Although previous data have shown prompt RV 
remodeling with decrease in RV volumes and mass after 
PVR,[14-16] a positive impact of PVR on outcome could 
not yet be demonstrated.[17] Bokma et al. analyzed the 
data of the INICATOR study to test the impact of PVR on 
clinical outcome.[18] Predefined guideline criteria for PVR 
were classified into “proactive” or “conservative” on the 
basis of the available literature and by consensus of the 
authors, and were used to determine the impact of PVR on 
outcomes. The study showed that PVR did not reduce the 
rate of death and/or sustained ventricular tachycardia 
(VT) during a follow-up of 5.3 years. In addition, greater 
number of clinical adverse events occurred, if PVR was 
performed in patients not meeting the consensus criteria.
Figure 2: Time interval between repair and first CMR in 
nonprogression (n = 65) and progressive dilatation groups (n = 20). 
CMR = Cardiac magnetic resonance
Figure 1: Box and whiskers plots comparing changes in indexed 
right ventricular end‑diastolic volume between first and last CMR of 
the progressive dilatation group (n = 20), RVEDV = Right ventricular 
end‑diastolic volume, CMR = Cardiac magnetic resonance
Table 3: Cardiac magnetic resonance parameter of 
the dilatation group (n=20)
First CMR Last CMR P
RVEDV
i
 (ml/m2) 154 (87‑237) 184 (128‑260) <0.001
RVESV
i
 (ml/m2) 83 (23‑186) 96 (58‑189) <0.001
RVEF (%) 49 (22‑62) 46 (27‑58) 0.69
LVEDV
i
 (ml/m2) 80 (57‑98) 85 (72‑105) 0.002
LVESV
i
 (ml/m2) 34 (23‑53) 40 (26‑61) 0.099
LVEF (%) 55 (44‑67) 56 (42‑66) 0.48
CMR: Cardiac magnetic resonance, BSA: Body surface area, RVEDV
i
: 
Right ventricular end‑diastolic volume indexed for BSA, RVESV
i
: Right 
ventricular end‑systolic volume indexed for BSA, RVEF: Right ventricular 
ejection fraction, LVEDV
i
: Left ventricular end‑diastolic volume indexed 
for BSA, LVESV
i
: Left ventricular end‑systolic volume indexed for BSA, 
LVEF: Left ventricular ejection fraction
Table 2: Cardiac magnetic resonance volumetric 
parameters (indexed) of the overall population 
(n=85)
First CMR Last CMR P
RVEDV
i
 (ml/m2) 150 (81‑249) 150 (82‑260) 0.11
RVESV
i
 (ml/m2) 75 (20‑186) 76 (39‑189) 0.31
RVEF (%) 49 (22‑68) 50 (18‑68) 0.72
LVEDV
i
 (ml/m2) 78 (56‑137) 81 (57‑128) 0.17
LVESV
i
 (ml/m2) 34 (23‑68) 35 (18‑61) 0.45
LVEF (%) 57 (43‑70) 57 (40‑71) 0.62
CMR: Cardiac magnetic resonance, BSA: Body surface area, RVEDV
i
: 
Right ventricular end‑diastolic volume indexed for BSA, RVESV
i
: Right 
ventricular end‑systolic volume indexed for BSA, RVEF: Right ventricular 
ejection fraction, LVEDV
i
: Left ventricular end‑diastolic volume indexed 
for BSA, LVESV
i
: Left ventricular end‑systolic volume indexed for BSA, 
LVEF: Left ventricular ejection fraction
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Other recent  data have shown that early favorable 
RV remodeling is followed by recurrent gradual RV 
enlargement toward pre-PVR values with a decline in 
global RV systolic function. This late adverse remodeling 
becomes relevant 7–10 years after implantation and is 
associated with increasing regurgitation and stenosis of 
the new bio-prosthetic pulmonary valve.[19] Percutaneous 
PVR is significantly less invasive than surgery and 
provides excellent short-term results; thus some 
advocate a more timely insertion of a new pulmonary 
valve in these patients.[20] However long-term results 
of valvular function after percutaneous PVR are not 
available yet. Meanwhile, an elevated prevalence of 
infective endocarditis after percutaneous pulmonary 
valve insertion has been reported; this seems to be higher 
than that in homograft valves and may be considered as 
an additional caveat for unnecessary PVR.[21]
For all these reasons,  the definition of the correct timing 
for PVR in rTOF patients remains a conundrum in modern 
congenital cardiology. On the basis of the results of our 
article and others,[5,6] the real challenge is to define the 
risk factors predicting a progressive RV deterioration 
and thus to recognize the correct patients for an early 
PVR. The evidence from the literature regarding this 
aspect is controversial. Even though some previous 
publications advocate the negative effect of the presence 
of a transannular patch, Rutz et al. did not describe 
any influence of different surgical techniques used for 
repair (transannular patch, subvalvular patch, and 
isolated infundibulectomy),[5] neither did we. Wald et al. 
reported the presence of a RV/PA conduit, higher RV 
volumes at baseline CMR, and lower EF% as predictors 
for RV deterioration.[6] In our smaller group of patients, 
we could not observe these findings. The inconsistency 
of the predictive factors reported in the literature may 
indicate that the RV volume alone may not be a sufficient 
parameter for selecting patients needing PVR.
There is increasing evidence  that LV parameters 
deserve more attention. The INDICATOR study has 
provided the first robust data for risk stratification of 
patients after TOF repair.[1] Not only RV hypertrophy 
and dysfunction but also LV dysfunction was a strong 
predictor for adverse outcome.[1] Dragulescu et al., using 
speckle tracking, found that LV myocardial deformation 
is decreased in rTOF patients despite a preserved LV 
EF%.[22] Similarly, Orwat et al., by using CMR-based 
feature tracking (FT) analysis, showed that LV strain is a 
significant predictor for life-threatening events or death 
in these patients, and its predictive value is superior 
to that of LV EF%.[23] With the retrospective design of 
our study, strain measurements of the left ventricles 
could not be performed; LV dilatation was observed in 
parallel to RV dilatation in the group with progressive 
dilatation, suggesting some unfavorable interventricular 
interaction [Table 3].
Novel imaging modalities  provide additional subtle 
parameters which may help to identify patients at risk. 
Hanneman et al. measured the myocardial extracellular 
volume (ECV) by using CMR in adult rTOF patients and 
found a correlation between an increased RV ECV and 
major adverse cardiovascular events.[24] CMR assessment 
of dyssynchrony and biventricular myocardial fibrosis 
showed that PVR reduces RV volumes, but has no effect 
on these two parameters.[25,26]
Considering  the increasing amount of available 
data, future direction of investigation should include 
many different imaging and bio-parameters, in order 
to understand the precise mechanisms that trigger 
unfavorable RV remodeling such as fibrosis, progressive 
RV enlargement, and function deterioration.[27] Hence, 
recently, Samad et al. used machine learning and applied 
different regression models to baseline variables of 
153 patients, for demonstrating that prediction of RV 
volume and function deterioration requires the inclusion 
of at least six baseline parameters, with LV being one of 
the most important.[28] The proof of this new approach has 
the potential of giving new insights regarding meaningful 
clinical decision-making and a potential paradigm change. 
Therefore, based on the current evidence from the 
literature, the optimal timing for interventions should 
be defined on the basis of multiple parameters, including 
clinical and functional status, conventional biventricular 
CMR parameters and novel imaging biomarkers, 
arrhythmias, and possibly up to genetic biomarkers.[27]
Limitations
This study has the limitation of being retrospective. Our 
population consisted of TOF cases mostly referred for 
advanced CMR imaging from outside referral centers. 
Thus, we had only limited influence on the subsequent 
clinical decision-making regarding a PVR, what allowed 
us to sequentially examine patients with a significantly 
dilated RV. On the other hand, we had only limited access 
to clinical information such as functional status, exercise 
capacity, and presence of arrhythmias, so that with our 
data, we cannot draw any conclusions on the influence 
of progressive RV dilatation on outcome.
Advance d image analysis, such as FT, was restricted by 
the multicentric design, with not totally homogenous 
imaging parameters, which was a limitation particularly 
regarding temporal resolution.
Volumetric changes during follow-up may represent 
variability of the measurements. We have obviated this 
potential source of error, by defining a significant change 
to be more than 20 ml/m2, corresponding to >10% of 
the value, which represents a sufficient range, based on 
the inter- and intra-observer variabilities of CMR volume 
measurements in rTOF patients previous published by 
our group.[11]
Hoelscher, et al.: Progression of right ventricular dilatation in Tetralogy of Fallot
299Annals of Pediatric Cardiology / Volume 13 / Issue 4 / October-December 2020
CONCLUSIONS
The vast majority of patients with PR after TOF repair 
and a dilated RV does not experience progressive 
RV dilatation during a follow-up of 3 years. RV 
dilatation appears to progress early after surgery and to 
subsequently stabilize. There is no evidence that surgical 
technique may influence the progression of dilatation. 
As RV progression is slow and function stable, a more 
conservative approach with follow-up imaging before 
PVR may be justified in clinically asymptomatic patients. 
The mechanisms triggering a progressive RV dilatation 
remain unclear.
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